Ladenburg Thalmann Financial Services’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-3,876
| Closed | -$13K | – | 5495 |
|
|
2018
Q3 | $13K | Buy |
3,876
+891
| +30% | +$3.21K | ﹤0.01% | 4170 |
|
|
2018
Q2 | $12K | Hold |
2,985
| – | – | ﹤0.01% | 4166 |
|
|
2018
Q1 | $12K | Sell |
2,985
-1,520
| -34% | -$7.08K | ﹤0.01% | 4166 |
|
|
2017
Q4 | $21K | Buy |
4,505
+100
| +2% | +$551 | ﹤0.01% | 3789 |
|
|
2017
Q3 | $32K | Sell |
4,405
-1,000
| -19% | -$7.19K | ﹤0.01% | 3407 |
|
|
2017
Q2 | $39K | Sell |
5,405
-470
| -8% | -$2.94K | ﹤0.01% | 3197 |
|
|
2017
Q1 | $36K | Hold |
5,875
| – | – | ﹤0.01% | 3164 |
|
|
2016
Q4 | $35K | Buy |
5,875
+100
| +2% | +$546 | ﹤0.01% | 3113 |
|
|
2016
Q3 | $31K | Buy |
5,775
+200
| +4% | +$1.08K | ﹤0.01% | 3123 |
|
|
2016
Q2 | $36K | Hold |
5,575
| – | – | ﹤0.01% | 2943 |
|
|
2016
Q1 | $25K | Buy |
5,575
+109
| +2% | +$435 | ﹤0.01% | 3116 |
|
|
2015
Q4 | $28K | Sell |
5,466
-1,349
| -20% | -$6.41K | ﹤0.01% | 2992 |
|
|
2015
Q3 | $25K | Buy |
6,815
+270
| +4% | +$1.81K | ﹤0.01% | 2971 |
|
|
2015
Q2 | $65K | Buy |
6,545
+304
| +5% | +$3.26K | ﹤0.01% | 2409 |
|
|
2015
Q1 | $80K | Buy |
6,241
+436
| +8% | +$5.61K | ﹤0.01% | 2226 |
|
|
2014
Q4 | $83K | Buy |
5,805
+1,154
| +25% | +$17.9K | ﹤0.01% | 2019 |
|
|
2014
Q3 | $64K | Sell |
4,651
-1,007
| -18% | -$15.4K | ﹤0.01% | 1881 |
|
|
2014
Q2 | $87K | Sell |
5,658
-2,155
| -28% | -$30.5K | ﹤0.01% | 1693 |
|
|
2014
Q1 | $133K | Sell |
7,813
-519
| -6% | -$7.83K | ﹤0.01% | 1343 |
|
|
2013
Q4 | $107K | Buy |
8,332
+1,221
| +17% | +$14.6K | ﹤0.01% | 1439 |
|
|
2013
Q3 | $74K | Sell |
7,111
-100
| -1% | -$890 | ﹤0.01% | 1569 |
|
|
2013
Q2 | $54K | Buy |
+7,211
| New | +$56.3K | ﹤0.01% | 1697 |
|
Ladenburg Thalmann Financial Services's KERX Position: Q4 2018 in Review
Ladenburg Thalmann Financial Services sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 3,876 shares — an estimated $13K sold.
Ladenburg Thalmann Financial Services first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $133K in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Ladenburg Thalmann Financial Services reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Ladenburg Thalmann Financial Services sold 3,876 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $13K.
- Ladenburg Thalmann Financial Services first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Ladenburg Thalmann Financial Services's Keryx Biopharmaceuticals Inc position peaked at $133K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2018, filed 14 Feb 2019.